Dosing of the first patient in the third cohort, along with comments on the second cohort;
Am I missing something then , dosing #6 was announced on the 25/6/15, but no comment yet on #4 or #5 biopsies (SH expressions)? I believe they are killing the shareholder value by with holding this data.
It looks more like a one trick pony every day, and the pony is kept in the stables.
Ann: App 4E / Full Year Statutory Accounts, page-62
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)